The effect of laparoscopic sleeve gastrectomy on morbid obesity and obesity-related comorbidities: A cohort study
Küçük Resim Yok
Tarih
2015
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Multidisipliner yönetilen bariyatrik cerrahi, cerrahi dışı tedavilerle karşılaştırıldığında morbid obezite ve obezite ile ilişkili ko-morbiditelerin tedavisinde etkin bir yöntemdir. Laparoskopik sleeve gastrektomi (LSG) ilk olarak süper-obez popülasyonda duodenal switch'li biliyopankreatik diversiyonun ilk basamağında yapılmaya başlanmıştır. Ancak son zamanlarda, LSG erken ve orta dönem sonuçlarının etkili olmasından dolayı sık kullanılan bir yöntem haline gelmiştir. Bu çalışmadaki amacımız, LSG yapılan ilk 73 hastamızdaki fazla kilo kaybı ve obezite ile ilişkili ko-morbiditelerin erken dönemdeki azalmasını değerlendirmektir.Gereç ve Yöntemler: Mart 2013 ve Mayıs 2014 arasındaki toplam 78 morbid obez hastanın ortalama vücut kitle indeksi 46,3 kg/m2'di (VKİ). Hastaların ortalama takip süresi 9 aydı ve 5 hastaya ulaşılamadığı için çalışmadan çıkarıldı. Hastalarımızın ameliyat öncesi ve sonrası ko-morbidite, VKİ, glukoz ve HbA1c seviyeleri, lipid profili kaydedildi. Hastalar ameliyat sonrası 1, 6 ve 12. aylarda değerlendirildi.Bulgular: Bu çalışmada hastaların ortalama fazla kilo kaybı yüzdesi %58'di ve ortalama serum glukoz, HbA1c, LDLkolesterol, trigliserid, insülin seviyeleri ve insülin direnci önemli oranda azaldı. Ortalama HDL-kolesterol seviyesi arttı.Sonuç: Laparoskopik sleeve gastrektomi, morbid obezitenin komorbitelerini düzeltmede efektif bariatrik ve metabolik cerrahi seçenek olabilir
Objective: Bariatric surgery with multidisciplinary management is a more effective method to treat morbid obesity and obesity-related comorbidities compared with nonsurgical treatments. Laparoscopic sleeve gastrectomy (LSG) was initially performed as the first stage of biliopancreatic diversion with duodenal switch in the super-obese population. in the past few years, however, LSG has been performed as a definitive procedure because of its promising early and midterm results. the aim of this study is to evaluate the efficacy of our initial LSG series of 73 patients on excess weight loss (EWL) and resolution of obesity-related comorbidities in short-term follow-up.Material and Methods: From March 2013 to May 2014, 78 morbid obese patients with an average body mass index (BMI) of 46.3 kg/m2 underwent LSG. There is a 9-month follow-up period on average. Five patients were excluded from the study, because they could not be contacted. Comorbidities, preintervention BMI, glucose, HbA1c, and lipid profiles were recorded at 1, 6, and 12 months postintervention.Results: After the surgery, the percent EWL was 58%. the mean serum glucose level, HbA1c level, LDL-cholesterol level, triglyceride level, insulin, and insulin resistance decreased significantly and the mean HDL-cholesterol level increased.Conclusion: For the resolution of comorbidities, LSG may be used as an effective bariatric and metabolic surgery
Objective: Bariatric surgery with multidisciplinary management is a more effective method to treat morbid obesity and obesity-related comorbidities compared with nonsurgical treatments. Laparoscopic sleeve gastrectomy (LSG) was initially performed as the first stage of biliopancreatic diversion with duodenal switch in the super-obese population. in the past few years, however, LSG has been performed as a definitive procedure because of its promising early and midterm results. the aim of this study is to evaluate the efficacy of our initial LSG series of 73 patients on excess weight loss (EWL) and resolution of obesity-related comorbidities in short-term follow-up.Material and Methods: From March 2013 to May 2014, 78 morbid obese patients with an average body mass index (BMI) of 46.3 kg/m2 underwent LSG. There is a 9-month follow-up period on average. Five patients were excluded from the study, because they could not be contacted. Comorbidities, preintervention BMI, glucose, HbA1c, and lipid profiles were recorded at 1, 6, and 12 months postintervention.Results: After the surgery, the percent EWL was 58%. the mean serum glucose level, HbA1c level, LDL-cholesterol level, triglyceride level, insulin, and insulin resistance decreased significantly and the mean HDL-cholesterol level increased.Conclusion: For the resolution of comorbidities, LSG may be used as an effective bariatric and metabolic surgery
Açıklama
Anahtar Kelimeler
Cerrahi
Kaynak
Ulusal Cerrahi Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
31
Sayı
4
